Levetiracetam is a new anti-epileptic drug that is currently not licensed for use in children. Studies in adults suggest that it may be a useful adjunctive treatment both in partial onset and generalised epilepsy. A retrospective case notes review of 26 children age 10 years and under with refractory epilepsy was undertaken to evaluate the efficacy and safety of the drug. The drug appeared to be most effective in children with partial onset seizures and least effective in those with myoclonic seizures. Sixty-one percent of patients showed a good response to levetiracetam with at least a 50% reduction in seizure frequency with two of these 26 children with previously refractory epilepsy becoming seizure-free. Levetiracetam was also found to be well-tolerated with very few reported side-effects.
INTRODUCTION
Levetiracetam (LEV), one of the newer-generation anti-epileptic drugs (AEDs), is reported to have a favourable pharmacokinetic profile, with rapid and almost complete oral absorption, nearly 100% bioavailability, minimal plasma protein-binding and a low incidence of both adverse side-effects and interactions with other AEDs 1, 2 . These properties make the drug a potentially useful adjunctive drug in the treatment of children with chronic epilepsy. Currently, LEV is only licensed for use in patients aged 16 years and over with partial onset seizures, although published data in teenagers and adults suggest that it is effective and well-tolerated as add-on therapy in both generalised and partial epilepsy [2] [3] [4] [5] .
To date, there are limited randomised clinical trial (RCT) and open data on the use of LEV in young children. This paper reviews retrospectively the use of the drug in children aged 10 years or under in a tertiary centre for paediatric epilepsy. The review describes an open, clinical evaluation of the effectiveness and safety of LEV and hopes to identify any particular difficulties with its use in a group of infants and young children with previously drug-resistant epilepsy.
PATIENTS AND METHODS
Data were obtained from the computerised database of the pharmacy department at the Royal Liverpool Children's Hospital (Alder Hey) over a 17-month period (from November 2001 to March 2003). All prescriptions were initiated or recommended by the paediatric neurologists who supervise seizure or neurology clinics both within the hospital but also in a number of peripheral, peripatetic neurology clinics in District General Hospitals.
Information was collected on the following: age and sex of the children; seizure type; epilepsy syndrome; underlying cause (when known); presence or absence of learning or physical difficulties; treatment with other AEDs; dose of LEV (starting and maximum dose) and duration of treatment.
Efficacy was based on seizure frequency and duration, with data obtained from seizure diaries completed by the child's parents and carers. In the absence of seizure diaries, efficacy was more crudely determined by whether the child and their usual carers considered that seizure frequency had improved. We also attempted to assess the response of each seizure type to LEV. Tolerability was assessed by documenting spontaneously-reported side effects by the child or their carers.
Haematological and biochemical data, including liver function and serum levels of LEV were not obtained because these parameters are not measured routinely in our patients with epilepsy.
The epilepsy syndromes were classified according to the International League Against Epilepsy classifications of 1981 and 1989 6, 7 .
Levetiracetam was always introduced in a once daily regime with a starting dose of 10-15 mg/kg/day. Further dose increases were undertaken in 10 mg/kg/day increments every 2 weeks. The drug was available in tablet form only (250 and 500 mg tablets). For children who were unable to swallow the tablets whole and for those with feeding gastrostomy tubes, it was recommended that either a 250 or 500 mg tablet (depending on the age of the child) was crushed and dissolved in either 5 or 10 ml of water. The corresponding volume of suspension would then be administered using either a syringe or 5 ml measuring spoon, often in conjunction with the child's preferred juice or semi-solid food (e.g. yoghourt).
RESULTS
Twenty-six patients aged 10 years and below were prescribed levetiracetam during this period. The characteristics of the patients are shown in Table 1 .
The mean duration of follow up was eight (range, 1-30) months. The median age of the children in this study was 7 years (range, 14 months-10 years). The median number of AEDs previously tried in these children was four (range, 1-9). Thirteen patients were receiving or had previously received, non-AED treatments, including oral pyridoxine (eight patients), piracetam (six patients-all because of frequent myoclonus/myoclonic seizures), prednisolone (five patients), intravenous immunoglobulins (one patient), the ketogenic diet (one patient) and vagal nerve stimulator (one patient).
The mean maintenance daily dose was 36.9 (range, 13.5-68.5) mg/kg/day. Information was only available on 25 patients; body weight data were missing on one patient. All 25 patients were simultaneously receiving between one (15 patients), two (six patients) or three (four patients) AEDs during their last clinic review. The most commonly used adjunctive AEDs included sodium valproate, lamotrigine, carbamazepine and one Of the 26 patients, 19 patients (73%) were experiencing at least three seizure types and six patients (23%), two seizure types. The response rates for each seizure type following the introduction of LEV is shown in Table 2 .
Partial-onset seizures appeared to show the best response; conversely, myoclonic seizures appeared to show the worst response rate.
Three quarters (19 children) of our patients remained on levetiracetam at the time of their last clinic review with two of these patients reporting complete seizure-freedom (both with a history of partial and secondarily generalised tonic-clonic seizures). One of these patients was a 4-year-old boy with Lennox-Gastaut Syndrome, maintained on 16.7 mg/kg/day of LEV in conjunction with lamotrigine and the second was a 10-year-old boy with tuberous sclerosis who was maintained on 13.5 mg/kg/day of LEV in conjunction with carbamazepine. Fourteen other patients reported a greater than 50% reduction in seizure frequency, three patients experienced less than 50% reduction, four showed no improvement and three experienced a deterioration in seizure frequency. Infantile spasms showed a 90% reduction in the one patient with (cryptogenic) West Syndrome although some partial seizures persisted; this patient received a maintenance dose of 30 mg/kg/day. The child with PEHO Syndrome (aged 2.5 years) and the child with Alpers' disease (aged 2 years) showed no response to LEV and the drug was discontinued after 6 and 9 weeks, respectively, due to lack of effect. Both of these patients had daily partial, secondarily generalised tonic-clonic and absence seizures.
Overall, 61% of our patients showed a good response to LEV with at least a 50% reduction in seizure frequency. There did not appear to be any obvious difference in response rates between specific epilepsies or epilepsy syndromes. Patients demonstrating a greater than 50% reduction in seizures included those with symptomatic generalised epilepsy (6 of 10 patients or 60%), symptomatic partial epilepsy (five of nine, or 55%), cryptogenic partial (two of two), Lennox-Gastaut Syndrome (two of four, or 50%) and West Syndrome (one of one).
In three patients (aged 5-10 years), seizures deteriorated following the introduction of LEV; all three demonstrated an increase in their pre-existing myoclonic seizures although in two of the three patients, other seizure types appeared to show some improvement. None of these patients received a dose in excess of 35 mg/kg/day.
Only one patient reported one adverse effect whilst receiving a dose of 35 mg/kg/day and this was excessive sleepiness that necessitated discontinuation of the drug. In four other patients (15% of the study group), LEV was withdrawn because of seizure-deterioration (three patients) and/or lack of effect (two patients).
DISCUSSION
This retrospective review of a group of young children with refractory epilepsy suggests that levetiracetam may be a useful adjunctive treatment in young children with refractory epilepsy. In this population it appeared to be most effective against partial onset seizures and least effective for myoclonic seizures, with in some patients, a deterioration in this specific seizure type.
It must be emphasised that our study population is heterogeneous in terms of seizure type, epilepsy syndrome, aetiology and additional neurological (physical and learning) difficulties. It is therefore inappropriate to comment on the effectiveness of LEV for specific epilepsy syndromes. In addition most patients had experienced and were continuing to experience multiple seizure types, that were both frequent and that had proved resistant to at least five other AEDs. The drug also appeared to be well-tolerated and finally, the children' carers had experienced no obvious difficulty in administering the drug, despite the lack of an infant or child-friendly preparation. In this type of population it would perhaps be unrealistic to expect that a new AED would result in any patient becoming seizure-free; a more realistic goal would be to improve seizure control without causing any serious adverse side-effects and possibly being able to withdraw one or more any pre-existing AEDs. Despite this understandably low expectation of success, two of our previously refractory patients became seizure-free and another 14 patients (53% of the entire group) demonstrated a greater than 50% reduction in seizure frequency. Furthermore, only one patient developed an adverse side-effect (drowsiness) that necessitated drug withdrawal and in seven patients at least one other AED was able to be successfully withdrawn, thereby reducing the AED 'burden' that these young children were exposed to.
Wheless and Ng in an open-label study of 39 paediatric patients with refractory epilepsy, found that LEV was most effective against partial onset seizures when used as add-on therapy 8 . In their study, 35% of patients discontinued the drug due to lack of efficacy or adverse effects. Lagae et al., who studied 21 patients with refractory childhood epilepsies found good overall efficacy of LEV for all seizure types, with, in contrast to our findings, the best response in those with myoclonic seizures 9 . The small numbers of patients and heterogeneous nature of the different study groups in terms of seizure types, epilepsy syndrome and aetiology may provide one explanation for these apparently discrepant findings.
Three of our patients showed a transient deterioration in seizure frequency, all with an increase in myoclonic seizures, and with no obvious association with either the initial dose or rate of titration of the drug. Withdrawal of the drug resulted in a return to pre-LEV levels. This effect has been reported recently-and apparently more dramatically-with 18% of 44 children demonstrating an exacerbation in seizure frequency including convulsive and complex partial status epilepticus and what the authors described as a new seizure type, apnoeas 10 . Seizure-aggravation by anti-epileptic drugs is a recognised phenomenon, particularly in children, and for which there are many potential causes 10, 11 . Further, and more extensive clinical experience will hopefully clarify this potentially very important issue.
The present study has also shown that LEV appears to be well-tolerated, at least in the short-term, with few reported side-effects, similar to previous studies 12, 13 . Somnolence has been reported as the most common side-effect 12, 13 , and this was the only reason why one of our patients was unable to tolerate the drug. None of our patients reported any behavioural or psychiatric effects, but it must be emphasised that the population was small and largely comprised of children with moderate, severe or profound learning difficulties, often in association with behavioural problems, which may have masked any minor or subtle emotional or frankly psychiatric side-effects.
Clearly, the study has a number of limitations, including the relatively small and markedly heterogeneous population studied within a specialist centre, the reliance on seizure diaries or carers' often subjective impressions to assess response and the lack of long-term follow up data. It would therefore be inappropriate to provide any definite recommendations on the precise use and role of LEV in young children. Nevertheless, these preliminary findings of the usefulness and practicality of using LEV in young children, reflect 'everyday' clinical practice and may be of some value. Larger prospective open-label studies with longer periods of follow up in homogeneous epilepsy syndromes will be necessary to either confirm or refute this initial clinical experience. Finally, it will be interesting to see whether further data on patients with infantile spasms confirm (or refute) our very preliminary findings, particularly following the future introduction of LEV in a more infant-friendly formulation (e.g. flavoured liquid or syrup or powder).
In conclusion, this small, retrospective review has suggested that, at least in the short term, LEV may be a useful adjunctive AED in children aged 10 years and younger with chronic intractable epilepsy. The drug appears to be most effective against partial seizures. Finally, it seems to be well tolerated with very few reported side effects.
